US Patent

US12053482 — Oral formulations of cytidine analogs and methods of use thereof

Method of Use · Assigned to Celgene Corp · Expires 2029-05-14 · 3y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions of cytidine analogs for oral administration that release the active ingredient in the stomach.

USPTO Abstract

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Drugs covered by this patent

Vidaza (azacitidine) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2950`	—	Vidaza
`U-2950`	—	Vidaza

Patent Metadata

Patent number: US12053482
Jurisdiction: US
Classification: Method of Use
Expires: 2029-05-14
Drug substance claim: No
Drug product claim: No
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.